James Parslow - Xenetic Biosciences CFO
| XBIO Stock | USD 3.37 0.03 0.88% |
CFO
Mr. James F. Parslow was appointed as Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer of the Company., effective April 24, 2017. Mr. Parslow, has served as the Companys Chief Financial Officer since April 3, 2017. Prior to joining the Company, he served as Chief Financial Officer, Treasurer and Secretary of World Energy Solutions, Inc., a publiclytraded businesstobusiness ecommerce company brokering energy and environmental commodities, from 2006 until its acquisition by EnerNOC, Inc. in 2015. From 2015 until April 2017, he served as an independent consultant providing interim chief financial officer services to multiple emerging technology companies since 2017.
| Age | 60 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | 945 Concord Street, Framingham, MA, United States, 01701 |
| Phone | 781 778 7720 |
| Web | https://www.xeneticbio.com |
James Parslow Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Parslow against Xenetic Biosciences stock is an integral part of due diligence when investing in Xenetic Biosciences. James Parslow insider activity provides valuable insight into whether Xenetic Biosciences is net buyers or sellers over its current business cycle. Note, Xenetic Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Xenetic Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Parslow over three months ago Acquisition by James Parslow of 20000 shares of Xenetic Biosciences at 3.99 subject to Rule 16b-3 | ||
James Parslow over six months ago Acquisition by James Parslow of 20000 shares of Xenetic Biosciences at 3.99 subject to Rule 16b-3 |
Xenetic Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.2725) % which means that it has lost $0.2725 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4548) %, meaning that it created substantial loss on money invested by shareholders. Xenetic Biosciences' management efficiency ratios could be used to measure how well Xenetic Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of March 2025, Return On Tangible Assets is likely to drop to -0.6. In addition to that, Return On Capital Employed is likely to drop to -0.73. At this time, Xenetic Biosciences' Total Assets are very stable compared to the past year. As of the 22nd of March 2025, Total Current Assets is likely to grow to about 8.7 M, while Non Current Assets Total are likely to drop about 298.2 K.Similar Executives
| Found 7 records | CFO Age | ||
| Bradley CPA | Tonix Pharmaceuticals Holding | 51 | |
| Peter Wolfe | ZyVersa Therapeutics | 57 | |
| Esq CPA | Phio Pharmaceuticals Corp | 79 | |
| M Morris | Tonix Pharmaceuticals Holding | N/A | |
| Ozan CFA | 180 Life Sciences | 32 | |
| Andrew Jones | NovaBay Pharmaceuticals | 53 | |
| Mark CPA | GeoVax Labs | 63 | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.27 |
Xenetic Biosciences Management Team
Elected by the shareholders, the Xenetic Biosciences' board of directors comprises two types of representatives: Xenetic Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xenetic. The board's role is to monitor Xenetic Biosciences' management team and ensure that shareholders' interests are well served. Xenetic Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xenetic Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Curtis Lockshin, Chief Scientific Officer | ||
| James Parslow, CFO, Principal Accounting Officer, Principal Financial Officer | ||
| Jeffrey Esq, President Director |
Xenetic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xenetic Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.62) % | ||||
| Operating Margin | (0.81) % | ||||
| Current Valuation | (729.27 K) | ||||
| Shares Outstanding | 1.54 M | ||||
| Shares Owned By Insiders | 19.05 % | ||||
| Shares Owned By Institutions | 6.43 % | ||||
| Number Of Shares Shorted | 6.51 K | ||||
| Price To Earning | (1.81) X |
Pair Trading with Xenetic Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xenetic Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xenetic Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Xenetic Stock
Moving against Xenetic Stock
The ability to find closely correlated positions to Xenetic Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xenetic Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xenetic Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xenetic Biosciences to buy it.
The correlation of Xenetic Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xenetic Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xenetic Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xenetic Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenetic Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.57) | Revenue Per Share | Quarterly Revenue Growth 0.005 | Return On Assets | Return On Equity |
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.